RUEL MARIANO: Open Payments
NPI 1114481785 · LAS VEGAS, NV. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,248 in 25 payments from 10 companies in 2025. Trend: 2023 $947 · 2024 $707 · 2025 $1,248
Food & beverage: $1,248
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 2 | $219 |
| ABBVIE INC. | 6 | $203 |
| E.R. Squibb & Sons, L.L.C. | 6 | $172 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $149 |
| Indivior Inc. | 1 | $125 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $122 |
| Novo Nordisk Inc | 1 | $119 |
| Collegium Pharmaceutical, Inc. | 4 | $77 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 2 | $36 |
| Forte Bio-Pharma LLC | 1 | $26 |
Products named: QULIPTA, COBENFY, CAPLYTA, SUBLOCADE, Kerendia, FARXIGA, Ozempic, BREZTRI.
Industry payments across NV — which companies pay providers there.
